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Abstract
The advent of electronic health records (EHR) and clinical decision support (CDS) has
brought numerous changes in the healthcare field and has improved how patients receive care.
The field of pharmacogenomics has made many breakthrough discoveries in the last few decades
and these new advances have immensely reduced the cost of genetic testing. As advances have
been made, researchers have discovered that individuals may respond to a medication differently
due to genetic variants. There is a shift in the medical field from a one size fits all model to a
personalized medicine model based on genetic information. Institutions have started to
incorporate genetic information in their EHR and CDS systems to aid clinicians in the
prescribing process. The rate of implementation is uneven among the institutions across the
United States. Healthcare institutions have encountered some challenges associated with
implementing pharmacogenomic data into CDS and EHR system. These challenges include lack
of clinician education about pharmacogenomic data, poor user interface, and lack of resources
for additional information for these alerts. If these challenges are overcome, there is great
potential for pharmacogenomic CDS systems to help improve patient care and reduce adverse
drug events.
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Implementation of Pharmacy Informatics
Chapter 1
Introduction
Health informatics has rapidly advanced in the last several decades and there has been
tremendous growth in the field. The U.S. National Library of Medicine as define health
informatics as an “interdisciplinary study of the design, development, adoption, and application
of IT-based innovations in healthcare services delivery, management, and planning” (HIMSS,
2014). There are several subdivisions of health informatics such as pharmacy informatics and
nursing informatics. Health informatics and associated fields are currently being utilized in a
variety of ways to provide a high level of patient care and improve outcomes. For example, a
large number of hospitals in the United States now utilize automated dispensing cabinets to
dispense medications in inpatient and outpatient pharmacies. The utilization of computerized
physician order entry (CPOE) system is also on the rise. These systems and many other systems
like it require health informatics to utilize them to their full potential.
Background of Problem
Numerous new technologies have been introduced in the healthcare field, and there has
been a shift in the healthcare world from a “one size fits all model to a precision personalized
regimen” (Klein, 2017). The Human Genome Project, which was conducted to map and
understand all of the genes of human beings, gave researchers an insight into human genetic
information (NIH, 2018). As technology and science advanced, over the years, scientists
discovered that some medications effect patients differently. Advancements in genetics research
revealed that patients metabolize medications differently based on their genetic makeup. A
medication that has gone through rigorous clinical trials can still cause adverse drug reactions
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(ADRs) in a certain patient population. These varying responses to drugs are typically due to
genetic variations. There are two types of genetics variations, inherited variants and acquired
variants (Ko, 2016). The inherited variants that encode drug-metabolizing enzymes, drug
transporters, drug targets, and human-leukocyte antigen (HLA) can affect individual response to
medication can impact how individual patients respond to certain medications. The acquired
mutations are associated with the development or progression, and they can “affect the drug
response of tumors that carry specific mutations, so called target therapy” (Ko, 2016).
Pharmacogenomics is the utilization of “current technology for precise determination of genetic
variants influence drug response, and to develop personalized strategies that maximize
therapeutic efficacy and assure drug safety” (Ko, 2016). Many large-scale genome-wide studies
have helped increase our understanding of the underlying mechanism of drug efficacy and
ADRs. Pharmacogenomics “is the driving force behind” the precision medication therapeutic
approach (Klein, 2017). Clinicians can utilize pharmacogenomics data to improve the clinical
outcomes of pharmacotherapy. For example, warfarin, which is an anticoagulation medication,
has been observed to be altered by two different genetic variations. Clinicians can utilize the
genetic information of a patient in regards to warfarin dosing to improve the initial dosing of the
medication and ensure that the patient does not have bleeding complications due to this
medication. Patient genetic data can be utilized to improve prescribing practices for many other
medications. The adoption and implementation of pharmacogenomics has been slow in
institutions in the United States. Pharmacogenomics can help decrease healthcare costs by
decreasing the number of adverse drug reactions and improve patient care by potentially
allowing providers to prescribe medications with a patient’s genetic data in mind.
Purpose of the Study
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Various advances have been made in the informatics field as well as the
pharmacogenomics field. Many healthcare organizations in the United States are obtaining
genetic information and utilizing that information in various ways. Some electronic health record
(EHR) systems are capable of integrating genomic data and using clinical decision support
(CDS) systems, however, there are many institutions that have not begun integrating genetic
information into an EHR system or the EHR system is not capable of integrating the genomic
data. The number of institutions utilizing pharmacogenomics data is increasing, however, their
approach to implementation of pharmacogenomics data varies across the board. The adoption of
pharmacogenomic CDS system integrated into an EHR system is currently largely limited to
large academic centers. The purpose of this study is to summarize the literature describing
implementation and utilization of pharmacogenomic information into electronic health records
and clinical decision support.
Significance of the Study
As advances in medications and pharmacogenomics occur, there will be a shift from a
one size fits all to a personalized medication approach. Healthcare institutions are moving
towards utilizing genomic data to provide better patient care. There are some institutions that are
currently utilizing pharmacogenomic information when prescribing certain medications,
however, the number of institutions implementing pharmacogenomic information into EHR and
CDS will increase over the years. For example, in oncology, genomic data is becoming
important for prescribing a treatment regimen because certain cancers respond to specific
treatments if they have that genomic variation, or the cancer may not respond to certain therapies
because of the variation. The genomic data of these patients needs to be incorporated into the
EHR system to allow clinicians to make appropriate decisions for their patients and provide
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better patient care. These advancements will aid in providing high-quality of care to patients.
Research Questions
The objective of this paper is to determine how pharmacogenomics data is being implemented
into EHR and CDS systems. How are institutions implementing pharmacogenomic data into their
EHR and CDS systems? How is this implementation changing prescribing practice?
Definition of Terms
Electronic Health Records (EHR) – an electronic version of a patient’s paper chart which
includes diagnosis, medication history, treatment histories, their clinical laboratory data, and a
wide variety of other information.
Clinical Decision Support (CDS) – provides clinicians, staff, patients, and others involved in the
care with knowledge and patient-specific information to improve health and health care.
Computerized Physician Order Entry (CPOE) – providers use a computer application to enter
and send treatment instructions such as laboratory and medication orders.
Pharmacogenomics (PGx) – study of how genes affect an individual’s response to drugs.
Adverse Drug Reaction (ADR) – the unwanted and undesired effects of a medication.
Limitations
The collection, implementation, and utilization of pharmacogenomic data has started to
increase, however, there are still many organizations that do not follow this practice. The
limitation of the study is that only a small number of institutions have fully implemented
pharmacogenomic data in their EHR system and are utilizing that data with their CDS system to
make changes in prescribing practices at those institutions. The implementation of such system is
also concentrated in large academic systems, which does not provide the full viewpoint of the
impact of utilizing a pharmacogenomic CDS system with an EHR system. There are still some
institutions that have not adopted a complete EHR system. There is limited data on the impact of
the implementation of Pharmacogenomics data into EHR and CDS systems.
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Chapter 2
Review of Literature
Introduction
Healthcare in the United States has seen drastic changes over the years. One major
change that is seen at most institutions is the use of information technology. The growing use of
information technology has led to the development of several branches in health informatics such
as pharmacy informatics and nursing informatics. The advancements in informatics and
information technology has increased the utilization of new technologies such as electronic
health records (EHR) and computerized physician order entry (CPOE) system. The adoption of
and EHR system has increased in healthcare institutions in the United States. These changes
have helped institutions improve patient care.
For years, there has been a view of a one size fits all model with drug therapy for
patients. With the advent of new technology, there has been a push towards personalized
medicine. The ultimate result of personalized medicine would be increased quality and safety of
care for patients. This systemic literature review is an effort to determine the implementation of
pharmacogenomics data into electronic health records at healthcare institutions across the United
States and determine whether prescribing practices have changed as a result of such
implementation.
Method
The literature review was conducted using several electronic sources such as PubMed,
Scopus, and the Web of Science. Various search terms were used to identify relevant articles
such as electronic health records, electronic medical records, and pharmacogenomics. A Medical
Subject Headings (MeSH) search was conducted on PubMed using “Electronic health records.”
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The MeSH terms were then used to build a search query, which yielded 34,391 articles. Another
MeSH term search was conducted using the search terms “Medical Records System.” The results
of the MeSH search were utilized to build a search query, which yielded 38,856. The above
queries were combined together, which resulted in 20,144 articles. A MeSH search was
conducted utilizing the term pharmacogenomics, and a search query was conducted utilizing the
MeSH search results, which generated 26,748 articles. The results of the “Electronic Health
Records,” “Medical Records System,” and “Pharmacogenomics” were combined to refine the
search query, which resulted in 113 articles. The search was further limited to articles from the
last 5 years, which narrowed the search to 65 articles. The same search query that was used in
PubMed was utilized in Scopus and Web of Science, which resulted in 81 and 1 articles
respectively. The total number of articles obtained from all three databases was 147 articles.
After duplicates were removed, there were a total of 140 articles remaining for this review.
Another search MeSH search was conducted utilizing the term Clinical Decision Support,
which was then used to build a search query, which resulted in 52,968 articles. This search query
was combined with the previous queries, and it resulted in 51 articles. The search was then
limited to articles from the last 5 years, which narrowed the search to 46 articles. The literature
articles utilized in this review discuss the implementation of pharmacogenomic information in
electronic health records and clinical decision support systems. in hospitals in the United States.
Inclusion Criteria
The article was included if it contained any of the following:
1. Published in the last 5 years
2. The article discussed utilizing pharmacogenomic data by implementing them into EHR
and CDS system
3. Article was published in the United States
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Exclusion Criteria
The article was excluded if it contained any of the following:
1. The article was not a research article such as an editorial, case study, comment piece, and
book section
2. The article was published in a language other than English
3. The article was published outside of the United States
Eligibility of the articles was initially determined based on the title and abstracts. Once it was
determined that the article met the inclusion criteria, full text articles were retrieved and studied
to determine their relevance. This search generated 10 articles that were relevant to the topic of
this literature review. Similar steps were followed to narrow the results of the second search.
Duplicates that were a part of the previous queries were removed and the remaining articles were
analyzed for this literature review, which resulted in a total of 3 additional articles because
majority of the articles were duplicates from the previous search query. Articles were included
and excluded if they did not meet the above inclusion criteria (Figure 1, Appendix 1). After
careful review, the search was narrowed to 13 articles (Table 1).
Population Studied
The articles chosen for this review had different types of populations that were studied.
Some articles studied prescribers and their response to employing pharmacogenomic information
with CDS while prescribing medications. For example, Devine et al presented clinicians with
hypothetical clinical scenarios and studied their prescribing practice based on the
pharmacogenomic data that was presented (Devine et al., 2014). Some articles studied the EHR
and CDS systems that presented the pharmacogenomic data to determine challenges in
implementing such systems and find potential solutions to tackle these challenges (Rosenman,
2017).
Survey Method
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There were many different survey methods utilized in the articles that were a part of this
review. Some studies utilized hypothetical clinical case scenarios to determine response of
prescribers to gene-drug pair that might require dosage adjustment. Some studies collected data
over a period of time to determine how many CDS alerts were generated and if those alerts led
clinicians to make changes in their prescribing practice. For example, Ubanyionwu et al studied
prescriber’s response to CDS alerts that were designed to prompt testing for a TPMT genetic
variance. Some studies sent surveys to providers to evaluate prescriber perspective on the
implementation and usefulness of pharmacogenomic testing in clinical practice.
Table 1: Comparison of Reviewed Studies
Author,
Year
Ubanyionwu
et al. (2018)

Objective, Participant
Single-center,
retrospective, chartreview

Caraballo et
al. (2017)

Overcome challenges
of PGx implementation
with comprehensive
and systematic
implementation model

Hicks et al.
(2016)

Development of
pharmacist-managed
pharmacogenomic
services

Manzi et al.
(2016)

Implementation of a
comprehensive clinical
PGx service

St Sauver et
al. (2016)

Provider response to
PGx CDS alerts
integration into EHR

Study Method

Results

Prescriber’s response
Clinical Decision Support
(CDS) alert designed to
prompt TPMT testing
Development and
implementation of PGx
organized into 8
interdependent components;
aspects of implementation
were assessed
CPIC guidelines for various
drug-gene pairs were
integrated into patient care;
custom rules and alerts were
developed and deployed to
EHR for providing
pharmacogenomic decision
support
CDS for medication ordering
and dispensing driven by
documented PGx variant
status in EHR;
159 clinicians were sent an
e-mail survey to understand
perspectives on the
implementation and use of
PGx testing in clinical
practice

9-month study period: 500 CDS alerts
generated: TPMT testing ordered in
20% of the cases; TPMT phenotyping
not ordered in 80% of the cases
18 drug-gene drug interactions
implemented in EHR; complete
adherence to the model;
implementation impacted
approximately 1,247 providers and
3,788 patients
Integrating just 3 genes over a 3month period identified 17 patients at
risk for severe adverse reactions, and
resulted in reduction of
pharmacotherapy to reduce the risk of
adverse events

CDS provided guidance to providers
for 31 patients with actionable PGx
variants
Survey response rate = 57%; 52% did
not expect to use or did not know
whether they would use PGx
information in future prescribing
practices; 53% of the clinicians felt
alerts were confusing, irritating,
frustrating, or difficult to find
additional information; 30% of the
providers that received a CDS alert
changed their prescription to an
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alternative medication
Nishimura et
al. (2016)

Create proof-of-concept
decision support alert
system generated from
PGx incidental findings

Overby et al.
(2015)

Determine clinical
impact of CDS system
embedded in EHR to
deliver PGx
information to
physicians
Determine if physicians
find CDS alerts for
PGx drug-gene
interactions useful and
assess perceptions of
usability

Nishimura et
al. (2015)

Decision support rules using
discrete, machine-readable
incidental finding results
programmed into an EHR
system
22 physicians participated in
the study; physicians
performed prescribing tasks
utilizing simulated clinical
case scenarios

Alerts for 48 pharmacogenomic
variants created; 94 participants
enrolled in the study, with 49
participants having one or more PGx
variant identified
83% of physicians saw an advantage
using PGx-CDS at the start of the
study and 94% at the end of the study;

52 physicians participated in
an online simulation and
questionnaire involving a
prototype alert for
clopidogrel and CYP2C19

4% of participants said they would
override alert; 92% agreed alerts were
useful; 87% found visual interface
appropriate; 91% felt timing of alert
appropriate; and 75% unfamiliar with
specific drug-gene interaction; 80%
preferred ability to order the
recommended medication within the
alert
Participants considered PGx
information important for prescribing
decisions, but the information needs
to be presented in a relevant and
useful manner
There is strong potential for PGx to
improve health and heath care and be
cost-effective, but there are many
challenges that need to be addressed
when bringing PGx into wider use

Devine et al.
(2014)

Evaluate a CPOE
system with PGx-CDS
alerts in a simulated
environment

Presented 7 cardiologists and
3 oncologists with five
hypothetical clinical case
scenarios

Rosenman et
al. (2017)

Describe challenges
and potential solutions
of implementing
programs to support
precision medicine

Caraballo et
al. (2015)

Clinical decision
support to implement
CYP2D6 Drug-Gene
Interaction

Danahey et
al. (2017)

Build and design a
user-friendly Genomic
Prescribing System
(GPS)

Descriptive case study of
implementation of
pharmacogenomics program
in an urban safety-net
hospital and its outpatient
clinics
Developed CDS rules to alert
prescribers based on PGx
results for CYP2D6 and
documentation of phenotype
and genotypes in the EHR
PGx information was
collected and external data
sets were integrated to build
the Genomic Prescribing
System

O’Donnell et
al. (2017)

Study the influence of
PGx alerts on
prescribing behaviors

Seventeen providers from 8
different medicine primary
care and subspecialty clinics
participated in the study

Total of 206 events triggered over
study period; 45% were unreadable;
implementation of CDS integrated in
EHR is feasible, but significant
challenges are present
The GPS had 257 CDS encompassing
112 genetic variants, 42 genes, and 46
PGx-actionable drugs; system had
nearly 2000 logins in 43 months since
inception; deployment of GPS
provided a tool that allowed point of
care genomic delivery with high
usability
2279 outpatient encounters were
analyzed; high PGx risk medications
were changed more often than
medications lacking PGx information;
medications with cautionary PGx
information also changed more
frequently; PGx information improved
prescribing in patterns aimed at
reducing patient risk
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Chapter 3
Results
The healthcare field has experienced numerous technological advances, which have
helped improve patient care. The introduction and implementation of EHR systems and CDS
systems have helped improve how clinicians provide care to their patients. Scientific discoveries
in the pharmacogenomic fields have helped scientists understand how medications may effect
patients differently. Implementing pharmacogenomic information into EHR and CDS systems
could potentially help providers appropriately prescribe certain medications and reduce the risk
of adverse events. The articles from this literature review discuss various topics related to
pharmacogenomics and EHR and CDS systems.
Ubanyionwu et al studied prescribers’ responses to CDS alerts designed to prompt Smethyltransferase (TPMT), which is an enzyme, genetic testing. There are several medications,
such as azathioprine, mercaptopurine, and thioguanine, that are inactivated by TPMT. Low
TPMT activity can lead to an accumulation of the active metabolites of these medications and
increased risk of toxicities. This is the reason scientists are advocating for preemptive TPMT
genetic testing before starting therapy with these agents. The authors conducted a single-center,
retrospective chart review to evaluate prescriber response to the TPMT genetic testing alert. The
healthcare institution had implemented CDS alerts that were designed to fire when a prescriber
ordered thiopurine. The studied found that during the study period, 500 CDS alerts were
generated, and TPMT testing was ordered in only 20% of the cases; in 80% of the cases, testing
was not ordered. The study found that a large number of alerts were neglected due to poor
alerting accuracy and alert fatigue. The authors also discovered that there was limited use of
online thiopurine doses by prescribers. The authors indicated that pharmacogenomic CDS
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enables clinicians to identify patients at risk for adverse reactions due to medications such as
thiopurine. This will help improve prescribing practices in the future.
A study by Caraballo et al developed a study to overcome technical and clinical
challenges associated with implementing pharmacogenomic data. The investigators organized
the implementation into eight independent components addressing “resources, governance,
clinical practice, education, testing, knowledge translation, clinical decision support (CDS), and
maintenance” (Caraballo et al., 2017). This study was conducted at the Mayo Clinic, which is a
large academic medical center. During the study period, the researchers reviewed 21 specific
drug-gene interactions, and implemented 18 of those into the EHR system as pharmacogenomicCDS interventions. They found complete adherence to the model, but variable production and
delay time. The researchers observed prescriber resistance to provide approval due to limited
literature to support implement pharmacogenomic testing. The study had a total of 1,247
providers that interacted with the pharmacogenomic CDS system during the study period, and
they observed that interventions were triggered for 3,788 unique patients. They also implemented
education resources to complement the drug-gene interactions to provide clinicians additional
resources. The authors concluded that a comprehensive model can support pharmacogenomic
implementation, but there are challenges that need to be addressed and overcome to expand the
usage of pharmacogenomics data.
Hicks et al described a pharmacist-managed pharmacogenomic services within a large
health system. The investigators used the Clinical Pharmacogenetics Implementation Consortium
(CPIC) guidelines for several drug-gene pairs and developed custom rules and alerts that were
implemented into an EHR system to provide pharmacogenomic CDS. The study was conducted
at the Cleveland Clinic Health System. They found that integrating 3 gene-drug pairs over a 3-
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month study period, they identified 17 patients at risk for severe adverse reactions. The
investigators found that clinicians recommended a pharmacogenomics consultation service to
address questions that are not gathered by CDS or data-mining services. These alerts
subsequently resulted in a change in the prescribing of the medication therapy to help reduce the
risk of adverse events in patients.
A study was conducted to outline the implementation of a comprehensive clinical
pharmacogenomics service in a pediatric hospital and the integration of CDS in the EHR. Manzi
et al describe how clinical decision support based on documented pharmacogenomic variant
status in EHR plays a role in ordering and dispensing medication. They found that CDS rules
built in the EHR provided guidance to healthcare providers for 31 patients with actionable
pharmacogenomic variant. The researchers concluded that if pharmacogenomic data is
incorporated into CDS properly, there is potential to impact incidence of adverse drug events.
A study by St Sauver et al was conducted to survey primary care clinicians’ response to
integration of pharmacogenomic CDS alerts in the EHR. The investigators sent surveys to
clinicians in the Mayo Clinic Primary Care Practice. The goals of the surveys was to analyze the
clinicians’ perception of implementation of pharmacogenomics and whether they thought this
would be useful in their practice. From the survey, they found that 52% of the providers did not
expect or did not know whether they would use pharmacogenomic information in future
prescribing practices. They also found that approximately 53% of the clinicians felt that the
alerts were confusing, frustrating, irritating, and it was not easy to find additional information
regarding the alert. Investigators reported that only 30% of the clinicians made a change in their
prescribing practice due to a CDS alert. The authors concluded that there was lack of clinician
comfort with integration of pharmacogenomic data into primary care and the pharmacogenomic
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CDS systems need to be user-friendly.
Nishimura et al set out to create a CDS system that incorporates pharmacogenomic data.
The investigators programmed CDS rules using machine-readable incidental findings into an
EHR system. They created alerts for 48 actionable pharmacogenomic variants in 11 genes. The
authors concluded that incidental findings could possibly be used to create CDS alerts, however,
tremendous resources are required to ensure that alerts are consistent with updated
pharmacogenomic literature.
Another study led by Nishimura with another group studied physician opinions on CDS
alerts for pharmacogenomic drug-gene interaction alerts and whether those alerts are useful to
them in their practice. They invited 52 physicians to participate in a simulation and a survey
which involved a CDS alert for clopidogrel and CYP2C10 drug-gene interaction. They found
that only 4% of the participants reported that they would override the alert. Approximately 92%
of the participants felt that the alerts were useful. The researchers concluded that many
physicians were open to pharmacogenomic CDS alerts, especially when they are user-friendly
and placed appropriately in the prescribing process.
Overby et al developed a study to investigate the clinical impact of using a CDS system
embedded in an EHR system to provide pharmacogenomic information to prescribers. The
investigators recruited 22 physicians to participate in the study. The study found that
approximately 83% of the participants found an advantage to using pharmacogenomic CDS
system before the study, and that number increased to 94% at the end of the study. The
researchers concluded that the pharmacogenomic CDS system needs to be user-friendly and
there needs to be a focus on content delivery, content, and tailoring to prescriber characteristics.
A computerized physician order entry (CPOE) system with pharmacogenomic CDS alerts
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was evaluated by Devine et al. They recruited a group of cardiologists and oncologists and
presented them with five hypothetical clinical case scenarios. The scenarios included a drug-gene
pair that would require dosage adjustment consideration. The participants reported that
pharmacogenomic data is important for prescribing decisions, however, the information needs to
be shown in a useful manner. The authors concluded that prescribers are more likely to
incorporate pharmacogenomic CDS when the information is presented in a user-friendly manner.
Rosenman et al explored the challenges associated with implementing new programs to
support precision medicine. In this descriptive study, the authors investigated the process of
implementing a pharmacogenomic program at a hospital and its outpatient clinics. The study
included 14 genes and 27 medications. The researchers discovered that some of the challenges
included clinician education and changes in standards of care, integrating pharmacogenomics
into EHR systems, and patient education and participation in the decision-making process. The
authors drew a conclusion that pharmacogenomics CDS has strong potential to improv health
care, but the challenges that are present need to be tackled to be able to utilize this valuable tool.
Caraballo et al published a brief article in which they integrated CDS alerts in an EHR
system for the gene encoding CYP2D6. They created a series of CDS rules to alerts providers
based on the results of pharmacogenomic testing for CYP2D6 and the documented genotypes
and phenotypes in the EHR. The CDS alerts fired for high or low activity of this gene. The alerts
also linked providers to additional pharmacogenomic education and alternative treatment options
if there were any available. During the study period, there were a total of 206 events that were
triggered by the CPOE system. They found that approximately 75% of the alerts were displayed
due to increased activity and approximately 25% due to decreased activity. They also found that
some alerts were displayed multiple times for the same drug/patient/provider interaction. The
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authors found that integrating CDS alerts into an EHR system is plausible, however, there
significant challenges. Clinicians need to be provided with education to understand these alerts
and prevent unnecessary and repetitive alerts.
A group of investigators, Danahey et al, built and designed a genomic prescribing system.
The investigators documented that a big implementation challenge lies in incorporating clinically
actionable genomic data in the EHR system. The goal of this project was to build a system that
was user-friendly and allowed the system to incorporate complex genomic data. They had
incorporated 257 CDS alerts, which included 112 genetic variants, 42 genes, and 46
pharmacogenomic actionable drugs. The CDS alerts presented users with three different colors to
denote the risk for each genomic result. The system had 2000 logins in 43 months. The authors
concluded that a user-friendly genomic prescribing tool allowed enabled point-of-care genomic
delivery with high rate of use.
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Chapter 4
Discussion
The articles that were selected for this review touched upon various topics related to
pharmacogenomics implementation into EHR and CDS systems. Many of the articles discussed
implementing a new pharmacogenomic CDS system within an EHR and evaluating clinician
interaction with these systems. The studies revealed that they were able to implement these
systems, however, they learned that there are many challenges that came to light during this
process. They needed to find solutions for these complications to make the system better.
There were many challenges that were reported in this studies. The common issues that
came up in these studies were lack of prescriber knowledge of pharmacogenomics and how it
would impact their prescribing practices. Some prescribers were able to see benefits in their
prescribing practice after they had participated in the study. The studies also found that users of
these systems wanted a user-friendly interface that provided the necessary information in the
prescribing process. The participants also wanted the system to provide them with additional
information regarding the specific alert and alternative medication if it is available.
The studies noted that there is potential for pharmacogenomics to decrease adverse drug
reactions and improve drug efficacy, however, there are several challenges that have kept the
incorporation rate slow. The challenges include reimbursement for genetic testing, developing an
infrastructure and standardized process to store, access, and interpret genomic data, and clinician
hesitation regarding the clinical and financial benefits of pharmacogenomics guided treatment
regimen. There is concern that the current EHR and CDS tools may not be able to handle the
influx of genomic data that is anticipated in the future, which means that additional infrastructure
will be required. A comprehensive strategy that incorporates all aspects of pharmacogenomic
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driven medicine, starting from the laboratory to data migration and clinical involvement to
multidisciplinary governance is required to tackle this challenge.
Institutions are starting to realize the benefits of implementing pharmacogenomic CDS
into their EHR system. They have learned that they can improve patient care if they incorporate
such system. There are challenges that need to be overcome when implementing these systems.
There are a lack of studies that evaluate the impact of pharmacogenomic CDS systems and the
true clinical impact is unclear. Many of the studies that are published only provide a short-term
impact of the pharmacogenomic CDS. Majority of the pharmacogenomic implementations are
currently limited to large academic medical centers. There is still a need for clinician-friendly
pharmacogenomic CDS systems and more research needs to be conducted on this topic.
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Chapter 5
Conclusion and Recommendations
Medical science is advancing at rapid pace and many new technologies are being utilized
to provide better care for patients. Numerous institutions have made extensive efforts to
implement pharmacogenomic CDS in clinical practice, however, they have faced many
challenges along the way, and the true clinical impact is unclear. The majority of the current
pharmacogenomic implementations have occurred in academic medical centers, which does not
provide a clear view of the impact of such system in other traditional healthcare institutions. If
institutions are able to implement user-friendly pharmacogenomic CDS integrated into an EHR
system, it has the potential to support pharmacogenomic driven medicine, which will help reduce
adverse drug reactions and improve therapeutic efficacy of the treatment regimen a patient
receives. There is a lack of published literature on this topic.
This literature search was extensive; however, another literature search should be
conducted to ensure that all studies that are related to this article are identified. Other search
terms that could potentially be incorporated in the search are computerized physician order entry
system and health information technology. Researchers need to conduct extensive studies to truly
identify the clinical impact of implementing pharmacogenomic CDS integrated into an EHR
system. These types of studies will help discover the true benefits of pharmacogenomic CDS and
aid in brining changes to the current standard of patient care.
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Appendix 1

Figure 1: Initial search query which included the search terms electronic health records, medical records system, and
pharmacogenomics.
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Figure 2: Second search query which included the search terms electronic health records, medical records system, and
pharmacogenomics, clinical decision support.
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Appendix 2
Database

PubMed

Scopus

Search Query
(((("Electronic Health Records"[Mesh] OR "Electronic Health Records" OR
"Electronic Health Record" OR "Electronic Medical Records" OR
"Electronic Medical Record" OR "Computerized Medical Record" OR
"Computerized Medical Records")) AND ("Medical Records Systems,
Computerized"[Mesh] OR "Medical Record Systems" OR "Computerized
Patient Medical Records" OR "Automated Medical Records System" OR
"Automated Medical Record System" OR "Computerized Medical Record
System" OR "Computerized Medical Records System" OR "Computerized
Medical Record Systems" OR "Computerized Medical Records Systems"
OR "Automated Medical Record System" OR "Automated Medical Record
Systems"))) AND ("Pharmacogenetics"[Mesh] OR "Pharmacogenetics" OR
"Pharmacogenomics" OR "Pharmacogenomic")
((((((("Medical Records Systems, Computerized"[Mesh] OR "Medical
Records Systems, Computerized" OR "Automated Medical Records
System" OR "Medical Record System, Automated" OR "Medical Record
Systems, Automated" OR "Medical Records System, Automated" OR
"Medical Records Systems, Automated" OR "Automated Medical Records
Systems" OR "Computerized Medical Record System" OR "Computerized
Medical Record Systems" OR "Computerized Medical Records System" OR
"Medical Record System, Computerized" OR "Medical Record Systems,
Computerized" OR "Medical Records System, Computerized" OR
"Computerized Medical Records Systems" OR "Automated Medical Record
System" OR "Automated Medical Record Systems"))) AND ("Electronic
Health Records"[Mesh] OR "Electronic Health Records" OR "Electronic
Medical Records" OR "Electronic Medical Record" OR "Medical Record,
Electronic" OR "Medical Records, Electronic" OR "Record, Electronic
Medical" OR "Records, Electronic Medical" OR "Electronic Health Record"
OR "Health Record, Electronic" OR "Health Records, Electronic" OR
"Record, Electronic Health" OR "Records, Electronic Health" OR "Medical
Records, Computerized" OR "Medical Record, Computerized" OR
"Computerized Medical Record" OR " Record, Computerized Medical" OR
"Records, Computerized Medical" OR "Computerized Medical Records")))
AND ("Decision Support Systems, Clinical"[Mesh] OR "Decision Support
Systems, Clinical" OR "Clinical Decision Support Systems" OR "Clinical
Decision Support" OR "Clinical Decision Supports" OR "Decision
Supports, Clinical" OR "Support, Clinical Decision" OR "Supports, Clinical
Decision" OR "Decision, Support, Clinical"))) AND
("Pharmacogenetics"[Mesh] OR "Pharmacogenetics" OR
"Pharmacogenetic" OR "Pharmacogenomic" OR "Pharmacogenomics")
(((("Electronic Health Records" OR "Electronic Health Records" OR
"Electronic Health Record" OR "Electronic Medical Records" OR

Results

65

31

81
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"Electronic Medical Record" OR "Computerized Medical Record" OR
"Computerized Medical Records")) AND ("Medical Records Systems,
Computerized" OR "Medical Record Systems" OR "Computerized Patient
Medical Records" OR "Automated Medical Records System" OR
"Automated Medical Record System" OR "Computerized Medical Record
System" OR "Computerized Medical Records System" OR "Computerized
Medical Record Systems" OR "Computerized Medical Records Systems"
OR "Automated Medical Record System" OR "Automated Medical Record
Systems"))) AND ("Pharmacogenetics" OR "Pharmacogenetics" OR
"Pharmacogenomics" OR "Pharmacogenomic")
((((((("Medical Records Systems, Computerized" OR "Medical Records
Systems, Computerized" OR "Automated Medical Records System" OR
"Medical Record System, Automated" OR "Medical Record Systems,
Automated" OR "Medical Records System, Automated" OR "Medical
Records Systems, Automated" OR "Automated Medical Records Systems"
OR "Computerized Medical Record System" OR "Computerized Medical
Record Systems" OR "Computerized Medical Records System" OR
"Medical Record System, Computerized" OR "Medical Record Systems,
Computerized" OR "Medical Records System, Computerized" OR
"Computerized Medical Records Systems" OR "Automated Medical Record
System" OR "Automated Medical Record Systems"))) AND ("Electronic
Health Records" OR "Electronic Health Records" OR "Electronic Medical
Records" OR "Electronic Medical Record" OR "Medical Record,
Electronic" OR "Medical Records, Electronic" OR "Record, Electronic
Medical" OR "Records, Electronic Medical" OR "Electronic Health Record"
OR "Health Record, Electronic" OR "Health Records, Electronic" OR
"Record, Electronic Health" OR "Records, Electronic Health" OR "Medical
Records, Computerized" OR "Medical Record, Computerized" OR
"Computerized Medical Record" OR " Record, Computerized Medical" OR
"Records, Computerized Medical" OR "Computerized Medical Records")))
AND ("Decision Support Systems, Clinical" OR "Decision Support
Systems, Clinical" OR "Clinical Decision Support Systems" OR "Clinical
Decision Support" OR "Clinical Decision Supports" OR "Decision
Supports, Clinical" OR "Support, Clinical Decision" OR "Supports, Clinical
Decision" OR "Decision, Support, Clinical"))) AND ("Pharmacogenetics"
OR "Pharmacogenetics" OR "Pharmacogenetic" OR "Pharmacogenomic"
OR "Pharmacogenomics")

Web of
Science

(((("Electronic Health Records" OR "Electronic Health Records" OR
"Electronic Health Record" OR "Electronic Medical Records" OR
"Electronic Medical Record" OR "Computerized Medical Record" OR
"Computerized Medical Records")) AND ("Medical Records Systems,
Computerized" OR "Medical Record Systems" OR "Computerized Patient
Medical Records" OR "Automated Medical Records System" OR
"Automated Medical Record System" OR "Computerized Medical Record
System" OR "Computerized Medical Records System" OR "Computerized

1

1
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Medical Record Systems" OR "Computerized Medical Records Systems"
OR "Automated Medical Record System" OR "Automated Medical Record
Systems"))) AND ("Pharmacogenetics" OR "Pharmacogenetics" OR
"Pharmacogenomics" OR "Pharmacogenomic")
((((((("Medical Records Systems, Computerized" OR "Medical Records
Systems, Computerized" OR "Automated Medical Records System" OR
"Medical Record System, Automated" OR "Medical Record Systems,
Automated" OR "Medical Records System, Automated" OR "Medical
Records Systems, Automated" OR "Automated Medical Records Systems"
OR "Computerized Medical Record System" OR "Computerized Medical
Record Systems" OR "Computerized Medical Records System" OR
"Medical Record System, Computerized" OR "Medical Record Systems,
Computerized" OR "Medical Records System, Computerized" OR
"Computerized Medical Records Systems" OR "Automated Medical Record
System" OR "Automated Medical Record Systems"))) AND ("Electronic
Health Records" OR "Electronic Health Records" OR "Electronic Medical
Records" OR "Electronic Medical Record" OR "Medical Record,
Electronic" OR "Medical Records, Electronic" OR "Record, Electronic
Medical" OR "Records, Electronic Medical" OR "Electronic Health Record"
OR "Health Record, Electronic" OR "Health Records, Electronic" OR
"Record, Electronic Health" OR "Records, Electronic Health" OR "Medical
Records, Computerized" OR "Medical Record, Computerized" OR
"Computerized Medical Record" OR " Record, Computerized Medical" OR
"Records, Computerized Medical" OR "Computerized Medical Records")))
AND ("Decision Support Systems, Clinical" OR "Decision Support
Systems, Clinical" OR "Clinical Decision Support Systems" OR "Clinical
Decision Support" OR "Clinical Decision Supports" OR "Decision
Supports, Clinical" OR "Support, Clinical Decision" OR "Supports, Clinical
Decision" OR "Decision, Support, Clinical"))) AND ("Pharmacogenetics"
OR "Pharmacogenetics" OR "Pharmacogenetic" OR "Pharmacogenomic"
OR "Pharmacogenomics")
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